Press Room

News / Jun 23, 2022

The Low Carbon Pledge

4th Annual Low Carbon Pledge Report

Green tree in front of Hovione R&D Center in Portugal. Hovione is a BITC Low Carbon Pledge signatory

Collaboration is key to achieving our climate goals.

Together with the Business in the Community Ireland Low Carbon Pledge, we continue to be committed to climate action as part of a movement of 70 businesses. Setting and working towards the achievement of science-based emissions reduction targets, together with peer-to-peer learning and collaboration, are some of the key actions we are taking to transition to a net-zero future.

Today the 4th Annual Low Carbon Pledge Report progress report was published sharing the steady progress of our collective movement.

Being part of this collective movement is strategic for Hovione Cork as we are committed to doing our part for a better world. As part of Hovione’s commitment to climate action, we are proud to be a Business in the Community Ireland Low Carbon Pledge signatory.

The Low Carbon Pledge is the first dedicated pledge generated by Irish businesses to set industry standards on sustainability and reduce carbon emissions. Originally launched in 2018, the Pledge has now evolved and calls on all Irish businesses to work collectively towards setting science-based targets and achieving our long-term climate goals of net-zero by 2050.

 

You can download a copy of the 4th Annual Low Carbon Pledge Report at BITC.ie

 

Find more about Sustainability at Hovione

 

 

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024